PATHWAYS Study: Puberty Suppression

Debate between Baroness Alexander of Cleveden and Baroness Merron

Wednesday 24th June 2026 Lords Chamber

[Baroness Merron (Lab)]

The noble Baroness gives me the chance to reiterate that all the questions are valid. We are dealing with a complex, sensitive and difficult issue. What matters is that we get to the right place. As the noble Baroness, Lady Cass, said, I know we are all agreed on protecting children and young people. That is our motivation.

The noble Baroness asked about consent. As I said, children can participate only with the consent of a parent or a guardian, and the children themselves must consent or assent. The individual circumstances and nature of a child will be closely considered as part of the consideration. That is absolutely crucial. Children and young people may participate only if they are not subject to any safeguarding concerns. I am happy to speak in greater detail to the noble Baroness. All of this will be extremely rigorous, and rightly so. When we talk about the trial, we are talking about volunteers—that is crucial. They can participate only if they have been deemed clinically appropriate by both the NHS care team and the national multidisciplinary team. There is, correctly, the opportunity at every level to consider every child or young person as an individual, which is so important.

[Baroness Alexander of Cleveden (Lab)]

As some noble Lords know, I have some experience in my own family of the challenges around gender dysphoria and the difficulties for the trans community. I also have the experience of my mother, who was a haematologist at a time when there were great controversies surrounding that discipline. I was struck by what the noble Baroness, Lady Cass, said: there are GPs, psychiatrists and paediatricians—all sorts of medical professionals—wrestling with what the evidence may or may not show. While this is an extraordinarily difficult area, does the Minister agree that, in a world where there have been difficulties in the recent past, the responsibility of legislators is to try to equip all those professionals in the future with a clinically approved and evidence-led approach? It is only by having a highly safeguarded trial that we will move forward in a way that supports professionals operating in this area. If we demonise those individuals, the risk is that we never secure the evidence we need for the future.

[Baroness Merron (Lab)]

I agree with that. In the Statement itself, the Secretary of State made the point that PATHWAYS is rightly one of the most scrutinised UK clinical trials of recent times. I am sure we all welcome that.

Healthy Life Expectancy

Debate between Baroness Alexander of Cleveden and Baroness Merron

Tuesday 20th May 2025 Lords Chamber

[Baroness Alexander of Cleveden]

To ask His Majesty’s Government what steps they are taking to reverse recent declines in healthy life expectancy, and to address poverty-related inequalities in life expectancy.

[The Parliamentary Under-Secretary of State, Department of Health and Social Care (Baroness Merron) (Lab)]

My Lords, it is unacceptable that who you are or where you live can impact healthy life expectancy. Reversing the decline in healthy life expectancy is a core part of this Government’s health mission. There is a long way to go but we are making good progress—exceeding our pledge to deliver an extra two million operations, scans and appointments by delivering well over three million, and addressing major health risks that particularly impact more deprived areas.

[Baroness Alexander of Cleveden (Lab)]

I thank my noble friend for her Answer. She may be aware that, this morning, the Health Foundation published a new international benchmarking report. It highlights that, in the 2010s, in all parts of the UK outside London, mortality rates increasingly lagged behind progress in the other 21 countries in the study and that, by 2021, mortality rates in the north-east and north-west of the UK were 20% higher than in the south-west. In light of this, will the Government heed the Health Foundation’s call for a new health inequality strategy that has a particular focus on those parts of the country that have faced long-term industrial decline?

[Baroness Merron (Lab)]

My noble friend raises an extremely important point about inequality. The Health Foundation report focusing on the 2010s shines a light on the need to drive action, which we are doing across government through our missions, with a very ambitious goal and the right approach of halving the gap in healthy life expectancy between the richest and poorest regions. Although I am certainly very interested in what the Health Foundation report says, further strategy is not needed at this time because of the approach we are taking. But I assure my noble friend that in addressing health inequalities, including in areas of past industrial decline, we will be driving economic growth and removing health-related barriers to health, wealth and prosperity.